CHRO 0.73 Chromocell Therapeutics Corporation
| Range: | 0.52-6.0 | Vol Avg: | 110746 | Last Div: | 0 | Changes: | -0.07 |
| Beta: | 0 | Cap: | 0.00B | Currency: | USD | Exchange: | AMEX |
| Sector: | Healthcare | IPO: | Fri Feb 16 2024 | Empoloyees: | 4 | ||
| CUSIP: | CIK: | 0001386026 | ISIN: | US1711261057 | Country: | US | |
| CEO: | Mr. Francis Knuettel II, M.B.A. | Website: | https://chromocell.com | ||||
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow